FOLFOX + FOLFIRI

FOLFOX + FOLFIRI refers to the sequential or combined use of two established multi-agent chemotherapy regimens for the treatment of advanced or metastatic colorectal cancer and other gastrointestinal malignancies. - **FOLFOX** consists of folinic acid (leucovorin), fluorouracil (5-fluorouracil, 5-FU), and oxaliplatin. - **FOLFIRI** consists of folinic acid (leucovorin), fluorouracil (5-fluorouracil, 5-FU), and irinotecan. Both regimens work by targeting rapidly dividing cells through different mechanisms: - Fluorouracil is an antimetabolite that disrupts DNA synthesis. - Oxaliplatin is a platinum-based agent causing DNA crosslinking. - Irinotecan inhibits topoisomerase I, preventing DNA replication. - Folinic acid enhances the cytotoxic effect of fluorouracil. The combination or sequence aims to maximize tumor response by using non-cross-resistant agents. This approach is standard in metastatic colorectal cancer management; patients may receive one regimen followed by the other upon disease progression[2][6][10]. In some protocols such as "FOLFOXIRI" all four drugs are given together[4][8], but "FOLFOX + FOLFIRI" typically refers to their use in sequence rather than simultaneous administration.

Other names

folinic acid + fluorouracil + oxaliplatin + folinic acid + fluorouracil + irinotecandoublet chemotherapy (FOLFOX plus FOLFIRI)sequential chemotherapy with FOLFOX and FOLFIRI